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Abstract
Background—Over 150 000 Malawians have started antiretroviral therapy (ART), in which first-
line therapy is stavudine/lamivudine/nevirapine. We evaluated drug resistance patterns among
patients failing first-line ART on the basis of clinical or immunological criteria in Lilongwe and
Blantyre, Malawi.
Methods—Patients meeting the definition of ART failure (new or progressive stage 4 condition,
CD4 cell count decline more than 30%, CD4 cell count less than that before treatment) from January
2006 to July 2007 were evaluated. Among those with HIV RNA of more than 1000 copies/ml,
genotyping was performed. For complex genotype patterns, phenotyping was performed.
Results—Ninety-six confirmed ART failure patients were identified. Median (interquartile range)
CD4 cell count, log10 HIV-1 RNA, and duration on ART were 68 cells/μl (23–174), 4.72 copies/ml
(4.26–5.16), and 36.5 months (26.6–49.8), respectively. Ninety-three percent of samples had
nonnucleoside reverse transcriptase inhibitor mutations, and 81% had the M184V mutation. The
most frequent pattern included M184V and nonnucleoside reverse transcriptase inhibitor mutations
along with at least one thymidine analog mutation (56%). Twenty-three percent of patients acquired
the K70E or K65R mutations associated with tenofovir resistance; 17% of the patients had pan-
nucleoside resistance that corresponded to K65R or K70E and additional resistance mutations, most
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commonly the 151 complex. Emergence of the K65R and K70E mutations was associated with CD4
cell count of less than 100 cells/μl (odds ratio 6.1) and inversely with the use of zidovudine (odds
ratio 0.18). Phenotypic susceptibility data indicated that the nucleoside reverse transcriptase inhibitor
backbone with the highest activity for subsequent therapy was zidovudine/lamivudine/tenofovir,
followed by lamivudine/tenofovir, and then abacavir/didanosine.
Conclusion—When clinical and CD4 cell count criteria are used to monitor first-line ART failure,
extensive nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor
resistance emerges, with most patients having resistance profiles that markedly compromise the
activity of second-line ART.
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Introduction
In the Malawi antiretroviral treatment program, over 150 000 patients have initiated first-line
antiretroviral therapy (ART) since 2001, the majority starting after ART became free of change
in 2004 [1,2]. Given the limited resources, the program relies on a public health approach for
initiation of ART using clinical staging and rarely uses CD4 cell counts as a basis for ART
initiation [3]. Similarly, identification of ART failure is based primarily on clinical criteria in
most settings or immunological criteria when CD4 cell counts are available. HIV-1 RNA levels
are not routinely monitored [3].
The first-line regimen in Malawi is stavudine (d4T), lamivudine (3TC), and nevirapine (NVP).
In the event of toxicity, one can substitute zidovudine (ZDV) for d4Tor efavirenz (EFV) for
NVP. The current second-line regimen is ZDV, 3TC, tenofovir (TDF), and lopinavir/ritonavir
(LPV/r), consistent with 2006 WHO ART guidelines [4]. A more recent WHO document on
second-line treatment suggests using TDF/3TC or abacavir (ABC)/didanosine (DDI) for
patients failing first-line treatment with a ZDV or d4T and 3TC backbone [5].
Early virological failure on a nucleoside reverse transcriptase inhibitor (NRTI) and
nonnucleoside reverse transcriptase inhibitor (NNRTI) regimen is associated with emergence
of the M184V mutation and an NNRTI resistance mutation in approximately 50–75% of
patients in resource-rich settings [6–8]. Continuation of a failing regimen may be associated
with more complex mutation patterns, as has been observed in several studies in developing
countries [9–13]. The number and pattern of resistance mutations may depend on the exact
components of the regimen, HIV-1 subtype [14], and the duration of failure. Substantial NRTI
resistance may occur, making empiric selection of second-line NRTI difficult.
Given that the Malawian program relies on clinical or immunological criteria for changing
ART, accumulation of multiple NRTI mutations is expected. We sought to describe the degree
of resistance among patients with virologically confirmed first-line ART failure and determine




The study was conducted in Malawi within the national ART program. Kamuzu Central
Hospital (KCH) is a tertiary referral hospital for the central region of Malawi located in
Lilongwe. The Lighthouse Trust clinic is the primary ART clinic for KCH. The Queen
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Elizabeth Central Hospital (QECH) is the tertiary referral hospital for the southern region of
Malawi, located in Blantyre. The ART clinic of QECH is coordinated by the Malawi College
of Medicine. The University of North Carolina (UNC) Project and the John Hopkins Project
are research and care centers serving as partners for the Lighthouse clinic and QECH,
respectively.
Study population
HIV-positive patients (age >13 years) who initiated ART with d4T/3TC/NVP within the
Malawi national ART program and were suspected of failure on the basis of clinical (new or
progressive stage 4 condition) or immunological (CD4 cell count decrease >30%, CD4 cell
count less than the pretreatment value) findings were screened from January 2006 to June 2007.
Those patients who were confirmed as treatment failures on the basis of the above criteria and
who had HIV-1 RNA of more than 1000 copies/ml on a sample obtained at the time of failure
formed the primary study population for resistance testing.
Procedures
Human experimentation guidelines of the US Department of Health and Human Services, those
of the Malawi National Health Sciences Research Committee and the UNC at Chapel Hill and
Heath Insurance Portability and Accountability Act regulations were followed in the conduct
of this study. For all patients, basic demographics, ART treatment history, and previous trends
in CD4 cell count were obtained. Blood samples for viral load, CD4 cell count, and plasma
storage were obtained at the initial assessment visit for treatment failure prior to the initiation
of second-line treatment. Genotyping was performed on all samples, and phenotyping was
performed only on samples with more than one NRTI mutation.
Laboratory evaluations
Specimens were processed in either the UNC Project laboratory in Lilongwe or the Johns
Hopkins laboratory in Blantyre. HIV-1 RNA levels were measured by the Roche Amplicor
HIV-1 RNA Monitor kit (version 1.5; Roche Molecular Diagnostics, Pleasanton, California,
USA). CD4 cell counts were measured using flow cytometry by either the Becton Dickinson
FACSCount system (Becton Dickinson, Mountain View, California, USA) or the EPICS-MCL
Beckman Coulter Pan-Leuco Gating method (Beckman Coulter, Brea, California, USA).
Plasma was stored at −80°C until shipment to the USA. HIV genotype testing was performed
by the UNC Center for AIDS Research Virology Core using the TruGene HIV-1 Genotyping
Kit (Siemens Medical Solutions Diagnostics, Tarrytown, New York, USA). Drug susceptibility
was assessed by the PhenoSenseHIV assay at Monogram Biosciences, Inc (South San
Francisco, California, USA).
Analysis
All statistical analyses were performed using Stata 8.2 (Stata Corporation, College Station,
Texas, USA). Simple descriptive statistics included means, medians, and proportions, as
appropriate. Student’s t test, Wilcoxon rank-sum, and chi-square methods were applied as
required.
For genotype analysis, mutations were generally categorized according to the International
AIDS Society-USA recommendations [15]. Samples with M184V, M184I, and M184V/I were
considered to have 3TC and emtricitabine (FTC) resistance. NNRTI mutations included
K103N, Y181C, Y181I, G190A, G190S, V108I, Y188L, V106M, P225H, and K103NS.
Additionally, K101E and G190E were also included as NNRTI mutations [16,17]. NRTI
mutations included K65R and K70E (associated with TDF resistance), thymidine analog
mutations (TAMs) M41L, D67N, K70R, L210W, T215Y, T215F, K219Q, and K219E, and
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multinucleoside mutations, including the 69 insertion complex and the 151 complex [15]. Virus
with 69 insertion or Q151M complex with K65R or K70E were considered pan-nucleoside
resistant by genotype. Mixtures that included a resistance mutation were considered resistant.
Factors associated with the emergence of K65R and K70E, pan-nucleoside resistance
mutations (69 insertion, Q151M complex with K65R and K70E), and the presence of three or
more TAM mutations were evaluated using logistic regression. Factors considered in the
models included sex, type of identification of failure (clinical vs. not clinical), clinic location,
ZDV use, HIV-1 RNA at time of failure identification, and CD4 cell count at time of failure
identification.
For phenotype analysis, for those NRTIs that have both upper and lower clinical cut-offs in
the Monogram assay (TDF, 4.0 and 1.4, DDI, 2.2 and 1.3, ABC, 6.5 and 4.5), we performed
one analysis using the lower cut-off and a second analysis whereby we categorized the virus
as resistant or sensitive on the basis of the upper cut-off. All drugs were considered to be
partially active if their fold change in 50% inhibitory concentration, was between the upper
and lower limit cut-offs. For 3TC(3.5), FTC(3.5), d4T(1.7), ZDV(1.9), EFV(3.0), and NVP
(4.5), a single lower cut-off was used. We evaluated whether three potential second-line NRTI
backbones, ZDV/3TC/TDF, FTC/TDF, and DDI/ABC, would be predicted to have activity
against the individual viral variant.
Results
Over the 18-month period, 203 patients had suspected treatment failure on the basis of clinical
and immunological criteria and had viral load performed. Of these, 88 patients were suppressed
(HIV RNA <400 copies/ml), six had HIV RNA between 400–1000 copies/ml, three had
previous protease inhibitor exposure, and 10 had insufficient stored sample. The 96 remaining
patients served as the basis for this evaluation. Among these 96 patients, most were identified
by CD4 cell count decline (87) or new or progressive WHO stage 4 conditions (16) or both.
Ninety-two patients received d4T/3TC/NVP as initial therapy, and four patients had received
ZDV/3TC dual therapy prior to initiation of d4T/3TC/NVP. Thirty patients had ZDV
substituted for d4T, and nine had EFV substituted for NVP because of toxicity. The median
CD4 cell count, HIV RNA, and time on ART were 68 cells/μl, 52 374 copies/ml [interquartile
range (IQR) 16913–138259], and 36.5 months (range 8–127 months), and 50% were women
(Table 1). Patients who were on ZDV at the time of failure evaluation had longer durations of
ART treatment (48.6 vs. 34.7 months, P <0.001) with a median of 27 months (IQR 10–42) of
d4T use prior to switch and a median ZDV treatment duration of 14.9 months (IQR 5.4–23).
Of the 96 samples, two did not amplify, leaving 94 samples that could be evaluated by
genotyping. All samples were subtype C. The median number of resistance mutations (any
class) was five (IQR 3–7) with a range of 0–11. Five samples had no mutations identified (Table
2). NNRTI mutations occurred in 93% of the samples. Two patients had HIV with only NNRTI
mutations. The median number of NNRTI mutations was two (range 0–3), and of those with
at least one NNRTI mutation (n =87), 39% had one, 52% had two, and 8% had three mutations.
The most frequent NNRTI mutations were Y181C (55%), G190A (30%), K103N (28%),
K101E (15%), Y188L (8%), V106M (7%), Y181I (6%), K103N/S (2%), P225H (1%), G190S
(1%), and G190E (1%). Among patients with exposure to NVP but not to EFV (n =85), the
most common mutations were Y181C (55%) and G190A (26%). Among those with exposure
to both NVP and EFV (n =9), K103N (33%) and G190A (33%) mutations were the most
common. Y181C was significantly more common among NVP-only-exposed patients (55 vs.
11%, P =0.012).
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The M184Vor M184I mutation was present in virus from 77 patients (81%), although never
as the only mutation. Fifteen patients (16%) had virus with M184V and NNRTI mutations
only.
The most common mutation pattern was M184V and NNRTI mutations with one or more
TAMs, which occurred in 56% of patients. Of the patients with TAM-containing virus (n =53),
28% had one, 28% had two, and 44% had three or more TAMs. The most frequent TAMs were
T215 F/Y (73%), D67N (53%), K70R (36%), M41L (36%), K219 Q/E (23%), and L210W
(23%). Patients who had ever received ZDV had more TAMs (1.8 vs. 1.2 mutations, P =0.055)
and were more likely to have at least three TAMs (19% for d4T vs. 36% for ZDV, P =0.09).
In spite of no known exposure to TDF, 23% (22/94) of patients acquired virus with the K70E
(n =4) or K65R mutations (n =18). Eighteen patients developed virus with the Q151M mutation,
and in 15 patients, the Q151M mutation was associated with either K65R or K70E. One patient
developed a T69 insertion. In total, 16 patients had pan-nucleoside-resistant virus, on the basis
of the presence of the K65R or K70E mutation in association with the Q151M complex or the
presence of a 69 insertion. Compared with those with ZDV exposure, the emergence of the
K65R, Q151M, and K70E mutations was more common in those exposed only to d4T: K65R
(24 vs. 7%, P =0.05), K70E (6 vs. 0%, P =0.183), and Q151M (24 vs. 7%, P =0.05).
No patient with a CD4 cell count more than 200 cells/μl or HIV-1 RNA less than 10 000 copies/
ml had pan-nucleoside-resistant virus. One-third of patients with HIV-1 RNA less than 10 000
copies/ml had TAMs. Only two of 30 patients who had ever received ZDV developed either
K65R/K70E or pan-nucleoside resistance mutations.
Univariate and multivariate analyses were performed to look for associations with the
emergence of pan-nucleoside resistance, at least three TAMS, or either K65R or K70E. A CD4
cell count of less than 100 cells/μl was strongly associated with emergence of K65R or K70E,
pan-nucleoside resistance, and the emergence of three or more TAMs (Table 3). However,
associations with ZDVuse were not consistently in the same direction. ZDV use was strongly
protective for the emergence of K65R or K70E. ZDV use was protective for the emergence of
pan-nucleoside resistance in the univariate analysis resistance, but the trend was no longer
significant in the multivariate analysis [odds ratio (OR) 0.13, 95% confidence interval (CI)
0.02–1.07]. Conversely, ZDV was associated with an increased risk for emergence of three or
more TAMs in the multivariate analysis (OR 3.4, 95% CI 1.7–10.97).
Phenotypic drug susceptibility was determined for 70 samples with complex genotypes. Given
the selection criteria, nearly all samples had high-level NNRTI resistance (96% for NVP and
83% for EFV) and 3TC resistance (97%). Substantial phenotypic resistance was demonstrated
for most other NRTI agents (Fig. 1). The majority of viruses (61%) were fully susceptible to
TDF, whereas fewer were fully susceptible to ZDV (37%), d4T (37%), ABC (33%), or DDI
(1%). Partial susceptibility of the virus isolates was noted for TDF (33%), DDI (29%), and
ABC (20%). Consistent with the genotypic findings, those with ZDV exposure were more
likely to retain full susceptibility to TDF (82 vs. 56%, P =0.05).
We evaluated the expected activity of NRTI combinations recommended by the WHO
considering only the phenotype results (Table 4) (n =70). Three NRTI combinations were
evaluated, including ZDV/3TC/TDF, FTC/TDF, and DDI/ABC, taking advantage of the
clinical cut-off available for TDF, ABC, and DDI (Table 4a–c). Table 5 includes an overall
assessment of activity, including only fully sensitive NRTI or sensitive NRTI and those with
partial susceptibility. Overall, the three-NRTI combination provided the greatest likelihood of
one or two active NRTIs in either analysis, although 30 and 6% would have no active NRTI
option depending on consideration of partial susceptibility (Table 5). Notably, the ABC/DDI
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combination performed poorly in either assessment, with neither NRTI active in 67% in the
more stringent analysis and 46% when partial susceptibility was considered.
Discussion
In this study, we confirmed that a high level of NRTI resistance could accumulate when ART
failure is identified by clinical and immunological criteria. Our novel and most ominous
finding, based on genotyping, was that 17% of patients would not be expected to have any
active NRTI agents remaining. The use of d4T in subtype C virus does not follow predictable
patterns in the emergence of mutations and appears to be promiscuous in its ability to select
for K65R and K70E (associated with TDF resistance), multiple TAM pathways, Q151M, and
T69 insertions [14,18].
D4T use was associated with the emergence of K65R and K70E mutations in 30% of patients.
Although initially described to emerge at low frequency in patients receiving TDF-containing
regimens [6,7], these mutations are now being identified in resource-poor settings where d4T/
3TC/NVP is the first-line regimen [9,10,13,19]. ZDV use was independently associated with
the lack of emergence of these mutations, consistent with observations that K65R increases
ZDV sensitivity and TAMs and K65R appear to be antagonistic [20–22]. Although in subtype
B virus, both thymidine analogs, d4T and ZDV, select for similar TAMs, our data demonstrate
that d4T-based initial therapy in patients infected with subtype C virus selects for a broader
array of mutations, including the K65R mutation, which may be because of differences in the
nucleotide sequence of subtype C virus in this region of reverse transcriptase [14,23]. ZDV
use, in contrast, was associated with the emergence of more than three TAMs. Higher levels
of viral replication and lower CD4 cell counts, possibly related to longer duration of virological
failure, are associated with K65R and other non-TAM NRTI mutations [24].
The higher proportion of extensive NRTI resistance in our survey, compared with other studies,
likely reflects a longer duration of failure of our patients. High-level resistance to NRTI agents
has been uncommonly reported after 12 months of d4T/3TC/NVP usage [19,25]. Compared
with data from South Africa or Thailand [9,10], our patients had longer duration on ART (36.5
vs. 10.8 or 19 months), lower median CD4 cell count (median 68 vs. 161.5 or 174 cells/μl),
and higher HIV-1 RNA levels (4.72 vs. 4.29 or 4.0 log10 copies/ml) at the time of failure,
suggesting that patients in our cohort had likely been failing on therapy longer or had higher
baseline levels of replication than these other cohorts with access to virological monitoring.
Additionally, we found the highest levels of resistance, as defined by at least three TAMs,
K65R or 70E, or pan-nucleoside resistance, among those with CD4 cell count less than 100
cells/μl. However, other than these indirect measures, we have no means of knowing the exact
amount of time these patients were failing at the time of evaluation.
D4T/3TC/NVP serves as the first-line regimen for the majority of sub-Saharan Africa because
of its low cost, its generic fixed-dose combination tablet, and the fact that it does not require
laboratory monitoring of side effects as treatment is being initiated. However, long-term
toxicities such as lactic acidosis, peripheral neuropathy, and lipoatrophy have raised concerns
about long-term safety. Our data demonstrate that d4T may also have negative effects with
respect to the emergence of resistance. To minimize the long-term side effects of d4T, a
proposed switch to ZDV-based therapy after 6 months once the patient is stabilized and the
chances for anemia are lower has been suggested [26]. Given our observation that ZDV
decreased the odds of TDF and pan-NRTI resistance, this same strategy may also prove useful
in preventing the emergence of pan-NRTI-resistant virus and preserving the use of TDF for
second-line therapy. However, although ZDV use is associated with decreased odds of pan-
nucleoside resistance, its use is associated with higher rates of virus with more than three TAMs
compromising other NRTI activity and also limiting NRTI choices for second-line treatment.
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Currently, WHO recommends FTC/TDF or ABC/DDI as the NRTI backbone of second-line
ART regimens to be used in resource-limited settings [4,5]. On the basis of the complexity of
assessing partial activity to ABC, DDI, and TDF using genotype analysis, we explored our
more complex genotypes with phenotypic analysis [27]. Our findings suggest that neither drug
would be fully active in these combinations in 67% of patients for ABC/DDI and 39% for FTC/
TDF. The addition of ZDV, as in the Malawi ART program, to 3TC and TDF is supported by
our findings and increases the likelihood of having two active NRTIs in the regimen,
particularly if this determination is based on the lower cut points of the phenotypic assay. Many
country programs, including that in Malawi, now use LPV/r for second-line regimens [3]. Data
on the response to second-line treatment, stratified by the presence of broad nucleoside
resistance, will be critical for guideline development and future research. Success of second-
line therapy may be heavily dependent on the LPV/r component, which has shown substantial
but less than optimal activity as initial monotherapy [28]. Outcomes of second-line therapy in
developing world settings that have more virological monitoring and different viral subtypes
cannot be extrapolated across all developing world settings as the activity of the nucleoside
component may vary substantially. Nucleoside analog may only add cost and toxicity. Low
success rates of second-line therapy in some settings raise the question of whether new classes
of drugs may be needed if viral monitoring is not available. Paradoxically, the absence of
virological monitoring may thwart the public health approach, that is, use of a single regimen
for most patients, for second and later lines of therapy. Although recent modeling has suggested
that virological monitoring would offer little additional benefit in terms of clinical outcomes,
it is not clear that the potential for 15–25% prevalence of multi-NRTI or TDF resistance or
both, and unknown subsequent clinical outcomes with limited active agents could be accounted
for with certainty [29].
The fact that we did not find any pan-nucleoside resistance in patients with HIV-1 RNA less
than 10 000 copies/ml, similar to other studies [24], supports the WHO guidelines of a
virological trigger of 10 000 copies/ml for changing therapy. However, when clinical and
immunological means are used to identify failures, as in our study, only 16% of the patients
fell into this category. The strength of our study is that we have the largest description of
resistance in a government program that uses clinical and immunological monitoring to define
ART failure and limits second-line treatment to central hospitals. Additionally, we have
included phenotype data to support the interpretation of the complex NRTI resistance patterns.
All patients who were initiated on second-line treatment at these clinics during the 18-month
study recruitment period were included. However, we acknowledge that many patients who
were failing virologically may not have been included in this study that identified patients only
through clinical and immunological means, and that patients failing by these criteria could be
missed in busy public health-based clinics. Therefore, the actual number of patients with
resistant virus is likely to be higher. However, if rapid progressors were preferentially selected
through our screening procedures, the complex resistance patterns may have been
overrepresented. As with all resistance studies, the genotype determined at the time of sampling
may not reflect archived virus with other resistance patterns. For patients on ZDV, some
mutations apparently selected by d4T (K65R, K70E) may have diminished to levels below the
limit of detection, resulting in an underestimate in the prevalence of these mutations. As the
phenotype cut-offs have been developed using patients primarily infected with subtype B, these
cut-offs may not apply to patients infected with other subtypes, but recent evidence suggests
no significant difference between subtype B and C [30]. However, this could influence our
findings on expected drug susceptibility.
In summary, the high rate of broad NRTI resistance among patients on the most common first-
line regimen in the developing world, monitored using clinical and immunological definitions
of ART failure, strongly supports the need for improvement in monitoring of ART failure, in
resource-poor settings. In lieu of virological monitoring, failing on ZDVappears to allow more
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options in terms of future treatment and argues for its consideration for broader rollout in favor
of d4T-based regimens. In settings where clinical monitoring is used to detect ART failure and
d4T-based regimens serve as the first line, the use of a ZDV/3TC/TDF backbone demonstrates
the best chance for activity of second-line ART.
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Fig. 1. Fold change in 50% inhibitory concentration for individual nonnucleoside reverse
transcriptase inhibitor and nucleoside reverse transcriptase inhibitor agents
The bold horizontal line for each drug represents the median fold change and the arrows indicate
the lower clinical cut-off or the biological cut-off, as applicable. Points clustered together at
high fold-change values represent viruses with high-level resistance; an arbitrary fold-change
value was assigned on the basis of the ratio between the highest drug concentration tested in
the assay and the reference virus IC50 in that assay run. 3TC, lamivudine; ABC, abacavir; d4T,
stavudine; DDI, didanosine; EFV, efavirenz; IC50, 50% maximal inhibitory concentration;
NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine.
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Table 1
Characteristics of clinical/immunological failure patients with confirmed virological failure (HIV-1 RNA >1000
copies/ml) (n = 96).
Variable Median or percentage
Age (years) 38 (IQR 31–45)




Log10 transformed HIV RNA (copies/ml) 4.72 (IQR 4.26–5.16)
 <10 000 16
 10 001–100 000 54
 >100 000 30









ART, antiretroviral therapy; IQR, interquartile range.
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Table 2
Patterns of mutations seen among patients with antiretroviral therapy failure in Malawi (n = 94). Full NRTI and
NNRTI resistance profiles available online on journal website.
Resistance patterna n
Wildtype virus (no mutations identified) 5
M184 only 0
NNRTI mutations only 2
M184V and NNRTI mutations only 15
NNRTI mutations ± 184V-containing virus and additional mutations
TAM-containing virus 53
K65R or K70E 22
K65R/K70E and TAM mutations 7
Q151M complex 18
Multi-nucleoside mutation combinations
Q151M complex and K65R/K70E mutations 15
69 insertion 1
Multi-nucleoside (Q151 and K65R/K70E or 69 insertion) 16
a
Categories are not mutually exclusive. NNRTI, nonnucleoside reverse transcriptase inhibitor; TAM, thymidine analog mutations.
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